Jens-Peter Marschner

Publication Activity (10 Years)

Years Active: 2022-2022
Publications (10 Years): 6

Top Topics

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Charlotte Rose Lemech, Ganessan Kichenadasse, Jens-Peter Marschner, Konstantinos Alevizopoulos, Marit Otterlei, Michael Millward
ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study. Oncogene 42 (7) (2022)
Charlotte Rose Lemech, Ganessan Kichenadasse, Jens-Peter Marschner, Konstantinos Alevizopoulos, Marit Otterlei, Michael Millward
ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study. Oncogene (2022)
Charlotte Rose Lemech, Ganessan Kichenadasse, Jens-Peter Marschner, Konstantinos Alevizopoulos, Marit Otterlei, Michael Millward
ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study. Oncogene 42 (7) (2022)
Charlotte Rose Lemech, Ganessan Kichenadasse, Jens-Peter Marschner, Konstantinos Alevizopoulos, Marit Otterlei, Michael Millward
ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study. Oncogene 42 (7) (2022)
Charlotte Rose Lemech, Ganessan Kichenadasse, Jens-Peter Marschner, Konstantinos Alevizopoulos, Marit Otterlei, Michael Millward
ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study. Oncogene 42 (7) (2022)
Charlotte Rose Lemech, Ganessan Kichenadasse, Jens-Peter Marschner, Konstantinos Alevizopoulos, Marit Otterlei, Michael Millward
ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study. Oncogene 42 (7) (2022)